SCHEMBL5652893

SCHEMBL5652893

COc1cc2nncc(-n3ncc4cc(N5CCOCC5)ccc43)c2cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.49
MAP4K1 Q92918 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
APP P05067 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
PIK3CA P42336 3/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
THRB P10828 2/20 0.38
POLB P06746 1/20 0.38
INSR P06213 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4980334 0.92 PDE10A (0.49) PDE10AMAP4K1SMN1; SMN2APPBCHE
SCHEMBL4795126 0.85 PDE10A (0.45) PDE10AMAP4K1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4794636 0.84 PDE10A (0.49) PDE10ASMN1; SMN2APPBCHEACHE
SCHEMBL4984909 0.81 PDE10A (0.50) PDE10AMAP4K1SMN1; SMN2APPBCHE
SCHEMBL5247526 0.79 PDE10A (0.61) PDE10ASMN1; SMN2APPBCHEACHE
SCHEMBL5653371 0.78 PDE10A (0.47) PDE10AALDH1A1KDM4ECYP3A4MAPT
SCHEMBL4982681 0.76 PDGFRB (0.44) PDE10APDGFRB
SCHEMBL5653771 0.74 KDR (0.41) PDE10APDGFRB
SCHEMBL5651961 0.73 PDE10A (0.56) PDE10ASMN1; SMN2KDM4EMAPTHSD17B10
SCHEMBL4977732 0.73 IRAK4 (0.42) PDE10ACYP3A4CYP2C19PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 US disclosed
WO-2007098214-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors PDE7A, PDE10A, PDE7B PDE10A 2/4885MAP4K1 2163/4885SMN1; SMN2 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.